• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172034 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
# X* J$ F+ D" j* f3 R  e' M; }" F
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
/ l/ E9 e- t- F' z* s3 u+ ^# B; |
' a2 l' w) `- H$ }7 i% Y7 Y9 I- l
Sub-category:
: |2 V& Y# _# M5 t; vMolecular Targets
) Q1 N0 T+ E) r' K8 Q  M+ c/ ]- a7 b5 |2 X
: y6 u6 S+ L' T8 {8 D& V
Category:  M) z; W, S6 O" a. `( s
Tumor Biology
0 A3 O- q. u% i8 `% B# N( N
9 E- J( f- N6 f& z
3 L" N) I1 \% i0 \Meeting:  n+ _% L3 n1 C( Z: M
2011 ASCO Annual Meeting
+ `$ g3 a/ U" K5 @, l$ [( E7 W' u3 k9 u  H* e7 c! @9 o7 O: i1 l

/ R2 g8 q1 K8 M- ySession Type and Session Title:% O- ^* O' [( {2 w/ n
Poster Discussion Session, Tumor Biology
2 d$ p! N: T. z5 Q: N# t' C$ j& |1 ^& S

# W; |) Z  K4 B, N6 NAbstract No:
2 E/ L6 j# }6 l% f# ?8 V10517
9 {5 r9 d+ ?& s$ h! c- [
5 D7 x+ h* n) E3 }9 d! u/ `% G6 }( x. p- p$ }+ t" x
Citation:
7 o2 a7 M1 f1 N$ e1 \J Clin Oncol 29: 2011 (suppl; abstr 10517) , X! I& m8 V$ h" k  u3 U' z5 H: J
5 L2 Z- ?* k6 P9 ^5 p/ A: p
; B, O6 j0 j1 U$ d
Author(s):
3 _# ?$ p* u. C  g+ n7 X5 `& pJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China $ s% c4 K' ^# n! c. d
! K% s" ]/ O6 w( w( o6 z* m( f

$ o6 C8 ~% l* q: w* s4 R& m, J# `
' }5 F+ A; ?  _. M+ v) JAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 R9 I6 p5 o+ m- I: `9 }
9 U- p3 \& g- E  v3 Q
Abstract Disclosures
  [. |: M! [9 p( H8 a3 O# f
* m  e' m5 D4 L! w3 G; }Abstract:
0 W/ h# i+ e/ z( w7 S2 [$ z
5 n. H1 a6 ^6 m* @8 t5 K! O" Q6 S5 `! t- d4 }
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
# g. }+ H- i/ B1 q. b9 ]8 @6 S' X# w1 X+ S$ v0 ^' e+ G

$ l- `" w: f( j" v
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 : t! x! T6 I% n5 K
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
: ]! J- W9 m( U; l  P4 V
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
/ m7 k3 x: H% A+ I8 o4 n9 w, ^; V易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。3 g& x5 ^$ y; j: Q
ALK一个指标医院要900多 ...
5 F" ~2 ]1 r: A
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
5 _, {0 T  B2 s+ s. K/ C4 Y
2 q1 q! v5 E3 a# \2 W, c' p' y现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表